Ligand Pharms Glucagon Stock Working Capital
| LGNXZ Stock | USD 0 0.00 0.00% |
Ligand Pharms Glucagon fundamentals help investors to digest information that contributes to Ligand Pharms' financial success or failures. It also enables traders to predict the movement of Ligand Pink Sheet. The fundamental analysis module provides a way to measure Ligand Pharms' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ligand Pharms pink sheet.
Ligand |
Ligand Pharms Glucagon Company Working Capital Analysis
Ligand Pharms' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, Ligand Pharms Glucagon has a Working Capital of 0.0. This indicator is about the same for the Other average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Commodity Channel Now
Commodity ChannelUse Commodity Channel Index to analyze current equity momentum |
| All Next | Launch Module |
Ligand Fundamentals
| Revenue | 277.13 M | |||
| EBITDA | 98.42 M | |||
| Net Income | 57.14 M | |||
| Cash Flow From Operations | 78.8 M | |||
| Total Asset | 1.3 B | |||
| Net Asset | 1.3 B |
About Ligand Pharms Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ligand Pharms Glucagon's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ligand Pharms using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ligand Pharms Glucagon based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Ligand Pink Sheet analysis
When running Ligand Pharms' price analysis, check to measure Ligand Pharms' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharms is operating at the current time. Most of Ligand Pharms' value examination focuses on studying past and present price action to predict the probability of Ligand Pharms' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharms' price. Additionally, you may evaluate how the addition of Ligand Pharms to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |